Given the clinical importance of immune checkpoint-based therapies for ccRCC and the fact that not all patients respond to these regimes, we believe that further investigation of the relationship between HIF-1α and HIF-2α status and the immune microenvironment is of potential therapeutic relevance. The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.